CytoGenix

CytoGenix was a biotechnology company based in Houston, Texas, that specialized in the development of synthetic DNA (synDNA) technology for therapeutic and diagnostic applications. The company's core innovation was a proprietary cell-free DNA production process designed to create high-purity DNA sequences more rapidly and safely than traditional bacterial fermentation methods. Their research pipeline primarily focused on DNA vaccines and RNA interference (RNAi) therapies targeting infectious diseases such as Hepatitis C, HIV, and Influenza. Despite demonstrating the potential of its synDNA platform in various pre-clinical models, the company faced significant financial and legal challenges, including high-profile trade secret litigation. These difficulties eventually led to the cessation of its active operations and its delisting from public markets.